BerGenBio ASA
OSL: BGBIO.OL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Olav Hellebo BBA, MBA
- Employees
- 13
- Headquarters
- Bergen, Norway
- IPO year
- 2017
- Market cap
- NOK 45.7M
- Website
- https://www.bergenbio.com
Loading BGBIO…
Loading profile data…Frequently asked questions about BGBIO
What does BerGenBio ASA (BGBIO.OL) do?
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19....
Where does BGBIO.OL trade?
BerGenBio ASA (BGBIO.OL) trades on the Oslo Stock Exchange.
What sector is BGBIO.OL in?
BerGenBio ASA (BGBIO.OL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BerGenBio ASA?
Olav Hellebo BBA, MBA is the chief executive officer of BerGenBio ASA (BGBIO.OL).
Where is BerGenBio ASA headquartered?
BerGenBio ASA is headquartered in Norway.
Does BGBIO.OL pay a dividend?
BerGenBio ASA (BGBIO.OL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BGBIO.OL go public?
BerGenBio ASA (BGBIO.OL) completed its initial public offering in 2017.